Company profile: UroMems
1.1 - Company Overview
Company description
- Provider of an active implantable electronic artificial urinary sphincter, UroActive, designed to compensate for sphincter insufficiency in patients with stress urinary incontinence. Uses a bionic platform with embedded smart, digital, and robotic systems to create patient-specific treatment algorithms, addressing clearly identified clinical needs impacting quality of life.
Products and services
- UroActive: An active implantable electronic artificial urinary sphincter that compensates sphincter insufficiency in stress urinary incontinence, using a bionic platform with embedded smart, digital, robotic systems creating a patient-specific treatment algorithm
- Bionic Platform: A bionic platform with embedded smart, digital, and robotic systems that powers UroActive and enables creation of a patient-specific treatment algorithm for stress urinary incontinence
- Patient-specific Treatment Algorithm: A patient-specific algorithm generated by UroActive’s bionic platform and embedded smart, digital, robotic systems to tailor sphincter function compensation in stress urinary incontinence.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to UroMems
American Medical Systems
HQ: United States
Website
- Description: Provider of diversified medical devices and procedures to treat incontinence, erectile dysfunction, benign prostatic hyperplasia (BPH), pelvic floor prolapse, and other pelvic disorders in men and women; a wholly owned subsidiary of Endo Pharmaceutical headquartered in Minnetonka, Minnesota.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full American Medical Systems company profile →
Dicot
HQ: Sweden
Website
- Description: Provider of drug discovery and development focused on LIB-01, a modern potency drug candidate for erectile dysfunction and premature ejaculation, aiming for longer duration, fewer adverse effects, and a differentiated mode of action. Activities include phase 1 safety/absorption trials and preparations for phase 2a, pharmacology studies with Pelvipharm, a toxicology program, and an advisory expert group for market profiling.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dicot company profile →
Francis Medical
HQ: United States
Website
- Description: Provider of minimally invasive water vapor ablation therapy for prostate, kidney, and bladder cancer. Its Vanquish therapy uses thermal energy stored in sterile water vapor to ablate cancerous tissue, aiming to minimize side effects such as urinary incontinence and erectile dysfunction. Clinical programs include the VAPOR 1 early feasibility study and VAPOR 2 pivotal study to support FDA submission for U.S. market clearance in localized, intermediate-risk prostate cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Francis Medical company profile →
UroLift
HQ: United States
Website
- Description: Provider of UroLift, a minimally invasive treatment for urinary symptoms caused by benign prostatic hyperplasia (BPH).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full UroLift company profile →
Levee Medical
HQ: United States
Website
- Description: Provider of urological devices to improve recovery outcomes post-prostatectomy, including the Voro Urologic Scaffold, a bioresorbable device placed during robotic prostatectomy to treat urinary incontinence by managing bladder neck geometry and maintaining urethral length.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Levee Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for UroMems
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to UroMems
2.2 - Growth funds investing in similar companies to UroMems
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for UroMems
4.2 - Public trading comparable groups for UroMems
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →